Capital Research Global Investors 13D and 13G filings for BioMarin Pharmaceutical Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-13 2:14 pm Purchase |
2024-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Capital Research Global Investors | 12,991,772 6.800% |
2,217,131 (+20.58%) |
Filing |
| 2024-02-09 5:46 pm Purchase |
2024-02-07 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Capital Research Global Investors | 10,774,641 5.700% |
5,123,640 (+90.67%) |
Filing |
| 2023-02-13 3:32 pm Sale |
2023-02-14 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Capital Research Global Investors | 5,651,001 3.000% |
-7,021,007 (-55.41%) |
Filing |
| 2022-01-10 12:04 pm Sale |
2022-01-10 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Capital Research Global Investors | 12,672,008 6.900% |
-9,521,519 (-42.90%) |
Filing |
| 2021-02-16 3:58 pm Purchase |
2021-02-16 | 13G | BioMarin Pharmaceutical Inc. BMRN |
Capital Research Global Investors | 22,193,527 12.200% |
189,462 (+0.86%) |
Filing |